EN PL
EDITORIAL ARTICLE
Update on COVID-19 vaccines and autoimmune-mediated rheumatic diseases
 
More details
Hide details
1
Department of Oral Diagnostic Sciences, University at Buffalo, NY, United States
 
 
Online publication date: 2021-08-13
 
 
Reumatologia 2021;59(4):203-205
 
 
REFERENCES (12)
1.
Hazlewood GS, Pardo JP, Barnabe C, et al. Canadian Rheumatology Association recommendation for the use of COVID-19 vaccination for patients with autoimmune rheumatic diseases. J Rheumatol 2021, DOI: org/10.3899/jrheum.210288.
 
2.
van der Heijde D, Daikh DI, Betteridge N, et al. Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Ann Rheum Dis 2018; 77: 829–832, DOI: 10.1136/annrheumdis-2017-212565.
 
3.
Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 2012; 11: 754–765, DOI: 10.1016/j.autrev.2012.02.001.
 
4.
Kennedy NA, Goodhand JR, Bewshea C, et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut 2021; 70: 865–875, DOI: 10.1136/gutjnl-2021-324388.
 
5.
Deepak P, Kim W, Paley MA, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv 2021, DOI: 10.1101/2021.04.05.21254656 [Preprint].
 
6.
Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases – Version 2. Arthritis Rheumatol 2021; 73: 1093–1107, DOI: 10.1002/art.41877.
 
7.
Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA 2021; 325: 1784–1786, DOI: 10.1001/jama.2021.4385.
 
8.
Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 2021, DOI: 10.1136/annrheumdis-2021-220272 [Online ahead of print].
 
9.
Haidar G, Agha M, Lukanski A, et al. Immunogenicity of COVID-19 vaccination in immunocompromised patients: an observational, prospective cohort study interim analysis. medRxiv 2021, DOI: 10.1101/2021.06.28.21259576.
 
10.
Thomas SJ, Moreira Jr. ED, Kitchin N, et al. Six month safety and efficacy of BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021, DOI: 10.1101/2021.07.28.21261159.
 
11.
Ibarrondo JF, Hofmann C, Fulcher JA, et al. Primary, recall, and decay kinetics of SARS-CoV-2 vaccine antibody responses. ACS Nano 2021, DOI: 10.1021/acsnano.1c03972 [Online ahead of print].
 
12.
Naaber P, Adamson A, Sepp E, et al. Antibody response after COVID-19 mRNA vaccination in relation to age, sex, and side effects. medRxiv 2021, DOI: 10.1101/2021.04.19.21255714.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top